The role of meta-analyses in assessing cancer treatments

European Journal of Cancer

Volumn 36, Issue 11, 2000, Pages 1351-1358

  Sylvester, R ^a   Collette, L ^a   Duchateau, L ^a  

^a EORTC DATA CENTER   (Belgium)

Author keywords

Cancer clinical trials; Individual patient data; Intergroup trials; Literature search; Meta analysis; Overview; Publication bias; Randomised clinical trials; Selection bias; Systematic review

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BUSULFAN; CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; FLOXURIDINE; FLUOROURACIL; HYDROXYUREA; IDARUBICIN; NILUTAMIDE; PREDNISONE; TAMOXIFEN; TOREMIFENE; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; BLADDER CANCER; BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CANCER THERAPY; COLORECTAL CANCER; ESOPHAGUS CANCER; HUMAN; LEUKEMIA; LUNG CANCER; MASTECTOMY; META ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; REVIEW; SOFT TISSUE SARCOMA;

EID: 0033920707     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00125-8     Document Type: Article

References (73)

1. Gelber R.D., Goldhirsch A. Meta-analysis. the fashion of summing-up evidence. Part I. Rationale and conduct Ann. Oncol. 2:1991;461-468.
2. Clarke M., Stewart L., Pignon J.P., Bijnens L. Individual patient data meta-analyses in cancer. Br. J. Cancer. 77:1998;2036-2044.
3. Duchateau L., Collette L., Sylvester R., Pignon J.P. Estimating number of events from the Kaplan-Meier curve for incorporation in a literature based meta-analysis. what you don't see you can't get Biometrics. 56:2000;237-243.
4. Parmar M.K.B., Torri V., Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat. Med. 17:1998;2815-2834.
5. Stewart L.A., Parmar M.K.B. Meta-analyses of the literature or of individual patient data. is there a difference? Lancet. 341:1993;418-422.
6. Begg C., Berlin J. Publication bias. a problem in interpreting medical data J. Roy. Stat. Soc. A. 151:1988;419-463.
7. Altman D. Statistics in medical journals. developments in the 1980s Stat. Med. 10:1991;1897-1913.
8. Simes R. Publication bias. the case for an international registry of trials J. Clin. Oncol. 4:1986;1529-1541.
9. Olkin G. Meta-analyses. reconciling the results of independent studies Stat. Med. 24:1995;457-472.
10. Stewart L.A., Clarke M.J. Practical methodology of meta-analyses (overviews) using updated individual patient data. Stat. Med. 14:1995;2057-2079.
11. Dickersin K., Scherer R., Lefebvre C. Identifying relevant studies for systematic reviews. Chalmers I., Altman D. Systematic Reviews. 1995;17-36 BMJ Publishing Group, London.
12. Lewis J., Machin D. Intention to treat - who should use ITT? Br. J. Cancer. 68:1993;647-650.
13. Statistical principles for clinical trials. Stat. Med. 18:1999;1905-1942.
14. Jeng G.T., Scott J.R., Burmeister L.F. A comparison of meta-analytic results using literature versus individual patient data. J. Am. Med. Assoc. 274:1995;830-836.
15. Proceedings of the workshop on methodological issues in overviews of randomized trials, May 1986. Stat Med 1987, 6, April-May.
16. Conference on meta-analysis in the design and monitoring of clinical trials. Stat Med 30 June 1996, 15.
17. Chalmers I., Altman D. Systematic Reviews. 1995;BMJ Publishing Group, London.
18. Treatment of Early Breast Cancer, Vol 1. Worldwide Evidence 1985-1990:1990;Oxford University Press, Oxford.
19. Thompson S.G. Why sources of heterogeneity in meta-analysis should be investigated. Br. Med. J. 309:1994;1351-1355.
20. Galbraith R. A note on graphical representation of estimated odds ratios from several clinical trials. Stat. Med. 7:1988;889-894.
21. Williams C. Evidence-based cancer care. Clin. Oncol. 10:1998;144-149.
22. Cochrane Cancer Network. In The Cochrane Library, Issue 1. Oxford, Update Software, 2000, Issue 1.
23. Cuzick J., Stewart H., Peto R.et al. Overview of randomised trials comparing radical mastectomy without radiotherapy against simple mastectomy with radiotherapy in breast cancer. Cancer Treat. Rep. 71:1987;7-14.
24. Cuzick J., Stewart H., Peto R.et al. Overview of randomised trials of postoperative adjuvant radiotherapy in breast cancer. Cancer Treat. Rep. 71:1987;15-29.
25. Cuzick J., Stewart H., Peto R.et al. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J. Clin. Oncol. 12:1994;447-453.
26. Effects of radiotherapy and surgery in early breast cancer. an overview of the randomised trials N. Engl. J. Med. 333:1995;1444-1455.
27. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. an overview of 61 randomized trials among 28896 women N. Engl. J. Med. 319:1988;1681-1692.
28. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 1992, 339, 1-15, 71-85.
29. Polychemotherapy for early breast cancer. an overview of the randomised trials Lancet. 352:1998;930-942.
30. Tamoxifen for early breast cancer. an overview of the randomised trials Lancet. 351:1998;1451-1467.
31. Gelber R.D., Cole B.F., Goldhirsch A.et al. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer. meta-analysis of quality adjusted survival Lancet. 347:1996;1066-1071.
32. Clahsen P.C., van de Velde C.J., Goldhirsch A.et al. Overview of randomized perioperative polychemotherapy trials in women with early-stage breast cancer. J. Clin. Oncol. 15:1997;2526-2535.
33. Ovarian ablation in early breast cancer. overview of the randomised trials Lancet. 348:1996;1189-1196.
34. Crump M., Sawka C.A., DeBoer G.et al. An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer. Breast Cancer Res. Treat. 44:1997;201-210.
35. Pyrhonen S., Ellmen J., Vuorinen J.et al. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer. Breast Cancer Res. Treat. 56:1999;133-143.
36. Portal vein chemotherapy for colorectal cancer. a meta-analysis of 4000 patients in 10 studies J. Natl. Cancer Inst. 89:1997;497-505.
37. Sakamoto J., Hamada C., Kodaira S., Nakazato H., Ohashi Y. Adjuvant therapy with oral fluoropyrimidines as main chemotherapeutic agents after curative resection for colorectal cancer. individual data meta-analysis of randomized trials Jpn. J. Clin. Oncol. 29:1999;78-86.
38. Mamounas E., Wieand S., Wolmark N.et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer. results from four National Surgical Adjuvant Breast and Bowl Project adjuvant studies (C-01, C-02, C-03, and C-04) J. Clin. Oncol. 17:1999;1349-1355.
39. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J. Clin. Oncol. 17:1999;1356-1363.
40. Modulation of 5-fluorouracil by leucovorin in patients with advanced colorectal cancer. evidence in terms of response rate J. Clin. Oncol. 10:1992;896-903.
41. Piedbois P, Buyse M for the Advanced Colorectal Cancer Meta-analysis Project. What can we learn from a meta-analysis of trials testing the modulation of 5-FU by leucovorin? Ann Oncol 1993, 4(Suppl. 2), S15-S19.
42. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J. Clin. Oncol. 16:1998;301-308.
43. Toxicity of fluorouracil in patients with advanced colorectal cancer. effect of administration schedule and prognostic factors J. Clin. Oncol. 16:1998;3537-3541.
44. Meta-analysis of randomised trials testing the biochemical modulation of 5-fluorouracil by methotrexate in metastatic colorectal cancer. J. Clin. Oncol. 12:1994;960-969.
45. Reappraisal of hepatic artery infusion in the treatment of non-resectable liver metastases from colorectal cancer. J. Natl. Cancer Inst. 88:1996;252-258.
46. Durand-Zaleski I, Roche, B, Buyse M, et al. for the Meta-analysis Group in Cancer. Economic implications of hepatic arterial infusion chemotherapy in treatment of nonresectable colorectal liver metastases. J Natl Cancer Inst 1997, 89, 790-795.
47. Thirion P, Wolmark N, Haddad E, Buyse M, Piedbois P for the Meta-analysis Group in Cancer. Survival impact of chemotherapy in patients with colorectal metastases confined to the liver: a re-analysis of 1458 non-operable patients randomised in 22 trials and 4 meta-analyses. Ann Oncol 1999, 10, 1317-1320.
48. Arnot S.J., Duncan W., Gignoux M.et al. Preoperative radiotherapy in oesophageal carcinoma. a meta-analysis using individual patient data (Oesophageal Cancer Collaborative Group) Int. J. Radiat. Oncol. Biol. Phys. 41:1998;579-583.
49. Pawinski A., Sylvester R., Bouffioux C., Kurth K.H., Parmar M.K.B., Bijnens L. A combined analysis of EORTC/MRC randomized clinical trials for the prophylactic treatment of TaT1 bladder cancer. J. Urol. 156:1996;1934-1941.
50. Does neoadjuvant chemotherapy improve the survival of patients with locally advanced bladder cancer? A meta-analysis of individual patient data from randomised trials. Br. J. Urol. 75:1995;206-213.
51. Maximum androgen blockage in advanced prostate cancer. an overview of the randomised trials Lancet. 355:2000;1491-1499.
52. Bertagna C., De Gery A., Hucher M., Francois J.P., Zanirato J. Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven double blind randomized double blind trials (1056 patients). Br. J. Urol. 73:1994;396-401.
53. Pignon JP, Bourhis J, Domenge C, Designé L on behalf of the MACH-NC Collaborative Group. Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: results of three meta-analyses using updated individual patient data. Lancet, 2000, 355, 949-955.
54. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukemia. Br. J. Haemat. 101:1998;100-109.
55. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia. overview of 42 trials involving 12 000 randomised children Lancet. 347:1996;1783-1788.
56. Chemotherapeutic options in chronic lymphocytic leukemia. a meta-analysis of the randomized trials J. Natl. Cancer Inst. 91:1999;861-868.
57. Interferon alfa versus chemotherapy for chronic myeloid leukemia. a meta-analysis of seven randomized trials J. Natl. Cancer Inst. 89:1997;1616-1620.
58. Pignon J.P., Arriagada R., Ihde D.C.et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N. Engl. J. Med. 327:1992;1618-1624.
59. Auperin A., Arriagada R., Pignon J.P.et al. Prophylactic cranial irradiation for patients with small cell lung cancer in complete remission. N. Engl. J. Med. 341:1999;476-484.
60. Chemotherapy in non-small cell lung cancer. a meta-analysis using updated data on individual patients from 52 randomised trials Br. Med. J. 311:1995;899-909.
61. Postoperative radiotherapy in non-small-cell lung cancer. systematic review and meta-analysis of individual patient data from nine randomised controlled trials Lancet. 352:1998;257-263.
62. The influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early stage Hodgkin's disease. a meta-analysis of 23 randomized trials involving 3888 patients J. Clin. Oncol. 16:1998;830-843.
63. Loeffler M, Brosteanu O, Hasenclaver D, et al. for the IDHD Overview Study Group. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. J Clin Oncol 1998, 16, 818-829.
64. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin and cisplatin chemotherapy of ovarian carcinoma. a meta-analysis J. Clin. Oncol. 9:1991;1668-1674.
65. Chemotherapy in advanced ovarian cancer. four systematic meta-analyses of individual patient data from 37 randomized trials Br. J. Cancer. 78:1998;1479-1487.
66. Adjuvant chemotherapy for localized resectable soft tissue sarcoma of adults. meta-analysis of individual data Lancet. 350:1997;1647-1654.
67. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer. a randomised controlled trial Lancet. 354:1999;533-540.
68. Wachter K. Disturbed by meta-analysis? Science. 241:1988;1407-1408.
69. Meinert C. Meta-analysis. science or religion? Controlled Clin. Trials. 10:1989;257S-263S.
70. Egger M., Davey Smith G. Misleading meta-analysis. Br. Med. J. 310:1995;752-754.
71. Eysenck H. Meta-analysis and its problems. Br. Med. J. 309:1994;789-792.
72. Pogue J., Yusuf S. Overcoming the limitations of current meta-analysis of randomized controlled trials. Lancet. 351:1998;47-52.
73. Jones D. Meta-analysis. weighing the evidence Stat. Med. 14:1995;137-149.